Preventive Oral Treatment of Episodic Migraine: An Overview
Migraine is a common primary headache disorder and Episodic migraine is characterized by the occurrence of up to 14 headache days in a month. The preventive treatment of migraine is useful in patients with frequent migraine attacks, impaired activities of daily living, failure of acute pain manageme...
Gespeichert in:
Veröffentlicht in: | Neurology India 2021-03, Vol.69 (Supplement), p.S51-S58 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | S58 |
---|---|
container_issue | Supplement |
container_start_page | S51 |
container_title | Neurology India |
container_volume | 69 |
creator | Ranganathan, Lakshmi N Ramamurthy, Guhan Kanthimathinathan, Shunmugasundaram |
description | Migraine is a common primary headache disorder and Episodic migraine is characterized by the occurrence of up to 14 headache days in a month. The preventive treatment of migraine is useful in patients with frequent migraine attacks, impaired activities of daily living, failure of acute pain management, disabling aura and limitations in the use of acute treatment. It is aimed at reducing headache frequency and intensity, improve response to acute treatment of migraine and improve the quality of life.
To analyze the evidence for the efficacy and tolerability of preventive oral drugs used in the management of episodic migraine.
A narrative review of the references were reviewed by searching the literature for the articles published in PubMed in English language using all the following MeSH keywords "preventive treatment", "preventive oral treatment", AND "episodic migraine", "migraine".
Out of articles identified in the search, 38 articles were reviewed for evidence and summarized. The various oral drugs used in the prevention of episodic migraine are antihypertensives (beta-blockers, calcium channel blockers and Angiotensin-converting enzyme inhibitors/Angiotensin receptor blockers), antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors), antiepileptic drugs (valproic acid, topiramate, lamotrigine) and other miscellaneous agents. HURT questionnaire and HALT 30 index are useful in assessing response to treatment in the follow up of migraine patients.
An appropriately chosen oral drug is useful in the preventive treatment of episodic migraine. In patients, who fail to respond to the preventive treatment, it is essential to review the diagnosis of migraine, titrate the dosage and duration of preventive treatment and ensure patient compliance. In those patients who fail to respond to monotherapy, polytherapy is a useful option to be considered. |
doi_str_mv | 10.4103/0028-3886.315985 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2769873332</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A662722654</galeid><sourcerecordid>A662722654</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-5a04f5d4bfd348e4bd7748ecd339036b574943c860c659f8d2c6da5a100c04cc3</originalsourceid><addsrcrecordid>eNptkc9LwzAUx4Mobk7vnqTguTPNS9NUT2PMHzCZh3kOWfI6MtZ2pl3F_96MTUUYOTzy8vm-8PgQcp3QIU8o3FHKZAxSiiEkaS7TE9JP8lzGnDJ2Svq_zz1y0TSrcAVI2DnpAacUEi775OHNY4dV6zqMZl6vo7lH3ZahE9VFNNm4prbORK9u6bWr8D4aVdGsQ985_LwkZ4VeN3h1qAPy_jiZj5_j6ezpZTyaxoYDa-NUU16kli8KC1wiX9gsC9VYgJyCWKQZzzkYKagRaV5Iy4ywOtUJpYZyY2BAbvdzN77-2GLTqlW99VX4UrFM5DIDAPZHLfUalauKuvXalK4xaiQEyxgTKQ9UfIRaYoVh-brCwoX2P354hA_HYunM0QDdB4yvm8ZjoTbeldp_qYSqnTS1s6J2VtReWojcHPbbLkq0v4EfS_ANpG6Nng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2769873332</pqid></control><display><type>article</type><title>Preventive Oral Treatment of Episodic Migraine: An Overview</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Ranganathan, Lakshmi N ; Ramamurthy, Guhan ; Kanthimathinathan, Shunmugasundaram</creator><creatorcontrib>Ranganathan, Lakshmi N ; Ramamurthy, Guhan ; Kanthimathinathan, Shunmugasundaram</creatorcontrib><description>Migraine is a common primary headache disorder and Episodic migraine is characterized by the occurrence of up to 14 headache days in a month. The preventive treatment of migraine is useful in patients with frequent migraine attacks, impaired activities of daily living, failure of acute pain management, disabling aura and limitations in the use of acute treatment. It is aimed at reducing headache frequency and intensity, improve response to acute treatment of migraine and improve the quality of life.
To analyze the evidence for the efficacy and tolerability of preventive oral drugs used in the management of episodic migraine.
A narrative review of the references were reviewed by searching the literature for the articles published in PubMed in English language using all the following MeSH keywords "preventive treatment", "preventive oral treatment", AND "episodic migraine", "migraine".
Out of articles identified in the search, 38 articles were reviewed for evidence and summarized. The various oral drugs used in the prevention of episodic migraine are antihypertensives (beta-blockers, calcium channel blockers and Angiotensin-converting enzyme inhibitors/Angiotensin receptor blockers), antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors), antiepileptic drugs (valproic acid, topiramate, lamotrigine) and other miscellaneous agents. HURT questionnaire and HALT 30 index are useful in assessing response to treatment in the follow up of migraine patients.
An appropriately chosen oral drug is useful in the preventive treatment of episodic migraine. In patients, who fail to respond to the preventive treatment, it is essential to review the diagnosis of migraine, titrate the dosage and duration of preventive treatment and ensure patient compliance. In those patients who fail to respond to monotherapy, polytherapy is a useful option to be considered.</description><identifier>ISSN: 0028-3886</identifier><identifier>EISSN: 1998-4022</identifier><identifier>DOI: 10.4103/0028-3886.315985</identifier><identifier>PMID: 34003148</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Activities of Daily Living ; Anticonvulsants ; Anticonvulsants - therapeutic use ; Antidepressants ; Antihypertensive drugs ; Drug therapy ; Headaches ; Humans ; Migraine ; Migraine Disorders - drug therapy ; Migraine Disorders - prevention & control ; Oral medication ; Prevention ; Quality of Life ; Topiramate - therapeutic use</subject><ispartof>Neurology India, 2021-03, Vol.69 (Supplement), p.S51-S58</ispartof><rights>COPYRIGHT 2021 Medknow Publications and Media Pvt. Ltd.</rights><rights>2021. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-5a04f5d4bfd348e4bd7748ecd339036b574943c860c659f8d2c6da5a100c04cc3</citedby><cites>FETCH-LOGICAL-c432t-5a04f5d4bfd348e4bd7748ecd339036b574943c860c659f8d2c6da5a100c04cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34003148$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ranganathan, Lakshmi N</creatorcontrib><creatorcontrib>Ramamurthy, Guhan</creatorcontrib><creatorcontrib>Kanthimathinathan, Shunmugasundaram</creatorcontrib><title>Preventive Oral Treatment of Episodic Migraine: An Overview</title><title>Neurology India</title><addtitle>Neurol India</addtitle><description>Migraine is a common primary headache disorder and Episodic migraine is characterized by the occurrence of up to 14 headache days in a month. The preventive treatment of migraine is useful in patients with frequent migraine attacks, impaired activities of daily living, failure of acute pain management, disabling aura and limitations in the use of acute treatment. It is aimed at reducing headache frequency and intensity, improve response to acute treatment of migraine and improve the quality of life.
To analyze the evidence for the efficacy and tolerability of preventive oral drugs used in the management of episodic migraine.
A narrative review of the references were reviewed by searching the literature for the articles published in PubMed in English language using all the following MeSH keywords "preventive treatment", "preventive oral treatment", AND "episodic migraine", "migraine".
Out of articles identified in the search, 38 articles were reviewed for evidence and summarized. The various oral drugs used in the prevention of episodic migraine are antihypertensives (beta-blockers, calcium channel blockers and Angiotensin-converting enzyme inhibitors/Angiotensin receptor blockers), antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors), antiepileptic drugs (valproic acid, topiramate, lamotrigine) and other miscellaneous agents. HURT questionnaire and HALT 30 index are useful in assessing response to treatment in the follow up of migraine patients.
An appropriately chosen oral drug is useful in the preventive treatment of episodic migraine. In patients, who fail to respond to the preventive treatment, it is essential to review the diagnosis of migraine, titrate the dosage and duration of preventive treatment and ensure patient compliance. In those patients who fail to respond to monotherapy, polytherapy is a useful option to be considered.</description><subject>Activities of Daily Living</subject><subject>Anticonvulsants</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Antidepressants</subject><subject>Antihypertensive drugs</subject><subject>Drug therapy</subject><subject>Headaches</subject><subject>Humans</subject><subject>Migraine</subject><subject>Migraine Disorders - drug therapy</subject><subject>Migraine Disorders - prevention & control</subject><subject>Oral medication</subject><subject>Prevention</subject><subject>Quality of Life</subject><subject>Topiramate - therapeutic use</subject><issn>0028-3886</issn><issn>1998-4022</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkc9LwzAUx4Mobk7vnqTguTPNS9NUT2PMHzCZh3kOWfI6MtZ2pl3F_96MTUUYOTzy8vm-8PgQcp3QIU8o3FHKZAxSiiEkaS7TE9JP8lzGnDJ2Svq_zz1y0TSrcAVI2DnpAacUEi775OHNY4dV6zqMZl6vo7lH3ZahE9VFNNm4prbORK9u6bWr8D4aVdGsQ985_LwkZ4VeN3h1qAPy_jiZj5_j6ezpZTyaxoYDa-NUU16kli8KC1wiX9gsC9VYgJyCWKQZzzkYKagRaV5Iy4ywOtUJpYZyY2BAbvdzN77-2GLTqlW99VX4UrFM5DIDAPZHLfUalauKuvXalK4xaiQEyxgTKQ9UfIRaYoVh-brCwoX2P354hA_HYunM0QDdB4yvm8ZjoTbeldp_qYSqnTS1s6J2VtReWojcHPbbLkq0v4EfS_ANpG6Nng</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Ranganathan, Lakshmi N</creator><creator>Ramamurthy, Guhan</creator><creator>Kanthimathinathan, Shunmugasundaram</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>202103</creationdate><title>Preventive Oral Treatment of Episodic Migraine: An Overview</title><author>Ranganathan, Lakshmi N ; Ramamurthy, Guhan ; Kanthimathinathan, Shunmugasundaram</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-5a04f5d4bfd348e4bd7748ecd339036b574943c860c659f8d2c6da5a100c04cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Activities of Daily Living</topic><topic>Anticonvulsants</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Antidepressants</topic><topic>Antihypertensive drugs</topic><topic>Drug therapy</topic><topic>Headaches</topic><topic>Humans</topic><topic>Migraine</topic><topic>Migraine Disorders - drug therapy</topic><topic>Migraine Disorders - prevention & control</topic><topic>Oral medication</topic><topic>Prevention</topic><topic>Quality of Life</topic><topic>Topiramate - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ranganathan, Lakshmi N</creatorcontrib><creatorcontrib>Ramamurthy, Guhan</creatorcontrib><creatorcontrib>Kanthimathinathan, Shunmugasundaram</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Neurology India</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ranganathan, Lakshmi N</au><au>Ramamurthy, Guhan</au><au>Kanthimathinathan, Shunmugasundaram</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preventive Oral Treatment of Episodic Migraine: An Overview</atitle><jtitle>Neurology India</jtitle><addtitle>Neurol India</addtitle><date>2021-03</date><risdate>2021</risdate><volume>69</volume><issue>Supplement</issue><spage>S51</spage><epage>S58</epage><pages>S51-S58</pages><issn>0028-3886</issn><eissn>1998-4022</eissn><abstract>Migraine is a common primary headache disorder and Episodic migraine is characterized by the occurrence of up to 14 headache days in a month. The preventive treatment of migraine is useful in patients with frequent migraine attacks, impaired activities of daily living, failure of acute pain management, disabling aura and limitations in the use of acute treatment. It is aimed at reducing headache frequency and intensity, improve response to acute treatment of migraine and improve the quality of life.
To analyze the evidence for the efficacy and tolerability of preventive oral drugs used in the management of episodic migraine.
A narrative review of the references were reviewed by searching the literature for the articles published in PubMed in English language using all the following MeSH keywords "preventive treatment", "preventive oral treatment", AND "episodic migraine", "migraine".
Out of articles identified in the search, 38 articles were reviewed for evidence and summarized. The various oral drugs used in the prevention of episodic migraine are antihypertensives (beta-blockers, calcium channel blockers and Angiotensin-converting enzyme inhibitors/Angiotensin receptor blockers), antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors), antiepileptic drugs (valproic acid, topiramate, lamotrigine) and other miscellaneous agents. HURT questionnaire and HALT 30 index are useful in assessing response to treatment in the follow up of migraine patients.
An appropriately chosen oral drug is useful in the preventive treatment of episodic migraine. In patients, who fail to respond to the preventive treatment, it is essential to review the diagnosis of migraine, titrate the dosage and duration of preventive treatment and ensure patient compliance. In those patients who fail to respond to monotherapy, polytherapy is a useful option to be considered.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>34003148</pmid><doi>10.4103/0028-3886.315985</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-3886 |
ispartof | Neurology India, 2021-03, Vol.69 (Supplement), p.S51-S58 |
issn | 0028-3886 1998-4022 |
language | eng |
recordid | cdi_proquest_journals_2769873332 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Activities of Daily Living Anticonvulsants Anticonvulsants - therapeutic use Antidepressants Antihypertensive drugs Drug therapy Headaches Humans Migraine Migraine Disorders - drug therapy Migraine Disorders - prevention & control Oral medication Prevention Quality of Life Topiramate - therapeutic use |
title | Preventive Oral Treatment of Episodic Migraine: An Overview |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T15%3A48%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preventive%20Oral%20Treatment%20of%20Episodic%20Migraine:%20An%20Overview&rft.jtitle=Neurology%20India&rft.au=Ranganathan,%20Lakshmi%20N&rft.date=2021-03&rft.volume=69&rft.issue=Supplement&rft.spage=S51&rft.epage=S58&rft.pages=S51-S58&rft.issn=0028-3886&rft.eissn=1998-4022&rft_id=info:doi/10.4103/0028-3886.315985&rft_dat=%3Cgale_proqu%3EA662722654%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2769873332&rft_id=info:pmid/34003148&rft_galeid=A662722654&rfr_iscdi=true |